Agomelatine STADA 25 mg filmomhulde tabletten

Land: Nederland

Taal: Nederlands

Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Werkstoffen:

AGOMELATINE CITROENZUUR SAMENSTELLING overeenkomend met ; AGOMELATINE

Beschikbaar vanaf:

Stada Arzneimittel AG Stadastrasse 2-18 61118 BAD VILBEL (DUITSLAND)

ATC-code:

N06AX22

INN (Algemene Internationale Benaming):

AGOMELATINE CITRIC acid COMPOSITION corresponding to ; AGOMELATINE

farmaceutische vorm:

Filmomhulde tablet

Samenstelling:

CELLULOSE, MICROKRISTALLIJN (E 460) ; CROSPOVIDON (E 1202) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; IJZEROXIDE GEEL (E 172) ; MACROGOL 6000 ; MAGNESIUMSTEARAAT (E 470b) ; MANNITOL (D-) (E 421) ; NATRIUMSTEARYLFUMARAAT ; POVIDON K 30 (E 1201) ; SILICIUMDIOXIDE (E 551) ; STEARINEZUUR (E 570) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171)

Toedieningsweg:

Oraal gebruik

Therapeutisch gebied:

Agomelatine

Autorisatie datum:

2018-10-29

Bijsluiter

1
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
AGOMELATINE STADA 25 MG FILMOMHULDE
TABLETTEN
Agomelatine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Agomelatine STADA 25 mg filmomhulde tabletten is and what it is
used for
2.
What you need to know before you take Agomelatine STADA 25 mg
filmomhulde tabletten
3.
How to take Agomelatine STADA 25 mg filmomhulde tabletten
4.
Possible side effects
5
How to store Agomelatine STADA 25 mg filmomhulde tabletten
6.
Contents of the pack and other information
1.
WHAT AGOMELATINE STADA 25 MG FILMOMHULDE TABLETTEN IS AND WHAT IT IS
USED FOR
Agomelatine STADA 25 mg filmomhulde tabletten contains the active
ingredient agomelatine. It belongs to
a group of medicines called
antidepressants and you have been given Agomelatine STADA 25 mg
filmomhulde tabletten to treat your depression.
Agomelatine STADA 25 mg filmomhulde tabletten is used in adults.
Depression is a continuing disturbance of mood that interferes with
everyday life. The symptoms of
depression vary from one person to another, but often include deep
sadness, feelings of worthlessness, loss
of interest in favourite activities, sleep disturbances, feeling of
being slowed down, feelings of anxiety,
changes in weight.
The expected benefits of Agomelatine STADA 25 mg filmomhulde tabletten
are to reduce and gradually
remove the symptoms related to your depression.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE AGOMELATINE STADA 25 MG
FILMOMHULDE
TABLETTEN
DO NOT TAKE AGOMELATINE STADA 25 MG FILMOMHULDE TABLETT

Productkenmerken

1
1
NAME OF THE MEDICINAL PRODUCT
Agomelatine STADA 25 mg filmomhulde tabletten
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains agomelatine-citric acid equivalent to
25 mg of agomelatine
Excipient with known effect:
Each tablet contains 0.2 mg sodium.
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Film-coated tablet.
Yellow, oblong, biconvex film-coated tablets 9.0 mm long, 4.5 mm wide
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of major depressive episodes. Agomelatine STADA 25 mg is
indicated in adults.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is 25 mg once daily taken orally at bedtime.
After two weeks of treatment, if there is no improvement of symptoms,
the dose may be increased to 50
mg once daily, i.e. two 25 mg tablets, taken together at bedtime.
Decision of dose increase has to be balanced with a higher risk of
transaminases elevation. Any dose
increase to 50 mg should be made on an individual patient benefit/risk
basis and with strict respect of
liver function test (LFT) monitoring.
Liver function tests should be performed in all patients before
starting treatment. Treatment should not
be
initiated if transaminases exceed 3 X upper limit of normal (see
sections 4.3 and 4.4).
During treatment transaminases should be monitored periodically after
around three weeks, six weeks
(end of acute phase), twelve weeks and twenty-four weeks (end of
maintenance phase) and thereafter
when clinically indicated (see also section 4.4). Treatment should be
discontinued if transaminases
exceed 3 X upper limit of normal (see sections 4.3 and 4.4).
When increasing the dosage, liver function tests should again be
performed at the same frequency as when
initiating treatment.
_Treatment duration_
Patients with depression should be treated for a sufficient period of
at least 6 months to ensure that they
are free of symptoms.
_Switching therapy from SSRI/SNRI antidepressant to agomelatine_
Patients may experience discontinuation